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September 2010820 Letters to the Editorarticles, and the pooled results of these reports, which suggested
improved short-term outcomes after endovascular repair of
rDTAA. Currently, we are performing a comparative study
regarding the outcomes of endovascular and open repair of
rDTAA at seven large referral centers in Europe and the United
States, to further investigate if endovascular repair of rDTAA
results in improved outcomes. In the absence of the results of
this multicenter study, or any other large comparative studies,
we believe that our meta-analysis provides more insights, and
perhaps better evidence than the small case series that are
available at this moment.
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Table. Study and patient characteristics
Study Reference
Randomized trials
Durazzoa J Vasc Surg 200;39:967-76
Schouten N Engl J Med 2009;361:980-9
Subtotal
Nonrandomized studies
Feringa 2006 Semin Cardiothorac Vasc Anesth 2
Feringa 2009 Arch Gerontol Geriatr 2009;48:11
Kennedy, asymptomatic Stroke 2005;36:2072-6
Kennedy, symptomatic Stroke 2005;36:2072-6
Le Manach, continued Anesth Analg 2007;104:1326-33
Le Manach, discontinued Anesth Analg 2007;104:1326-33
McGirt J Vasc Surg 2005;42:829-37
Poldermans Circulation 2003;107:1848-51
Schanzer J Vasc Surg 2008;47:774-81
van Gestel Am J Cardiol 2008;102:192-6
Subtotal
Total
CI, Confidence interval; MLR, multivariate logistic regression; NR, not rep
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Regarding “Preoperative statin therapy is associated
with improved outcomes and resource utilization in
patients undergoing aortic aneurysm repair”
McNally et al1 demonstrated, in their retrospective analysis of
401 patients undergoing elective abdominal aortic aneurysm re-
pair, that postoperative mortality rate was significantly decreased in
the open repair statin cohort compared with the nonstatin open
repair cohort and trended to be decreased in the endovascular
repair statin group. Previous meta-analyses,2,3 which combined
Patients
No. Age, y Male, %
100 67  10 79
497 66  11 75
10:25-31 511 64  11 75
1693 73  5 76
1252 Median, 71 (statin) 73 (control) 65
2031 Median, 70 (statin) 73 (control) 67
178 67  11 88
491 68  11 89
1566 72  10 63
480 Mean, 70 82
1404 69  12 64
3371 66  12 73
; OR, odds ratio; PS, propencity score.006;
6-20
orted
10 patients (10%) without surgery.
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suggested that preoperative statin therapy was associated with
lower postoperative mortality after vascular surgery. Since these
meta-analyses were conducted, however, results of a number of
controlled studies have been reported to date. In the Dutch
Echocardiographic Cardiac Risk Evaluation Applying Stress
Echocardiography III (DECREASE III) trial,4 a recent large
randomized double-blind placebo-controlled trial in patients
undergoing vascular surgery, perioperative statin therapy re-
duced not postoperative death but myocardial ischemia or the
composite of death from cardiovascular causes and myocardial
infarction. Combining not unadjusted but adjusted risk esti-
mates in nonrandomized studies, we performed an updated
meta-analysis of controlled studies of preoperative statin ther-
apy for the prevention of postoperative mortality in vascular
surgery.
Our comprehensive search identified 10 controlled studies of
preoperative statin therapy enrolling patients undergoing vascular
surgery (Table). We excluded nonrandomized studies reporting
only unadjusted risk estimates. Kennedy et al5 provided an ad-
justed OR separately in symptomatic and asymptomatic patients
undergoing carotid endarterectomy. Le Manach et al6 reported an
adjusted OR separately in patients who continued and discontin-
ued preoperative statin therapy after infrarenal aortic surgery.
Therefore, from the eight nonrandomized studies, 10 ORs ad-
justed for potential confounding using appropriate statistical
Table. Continued.
Surgery, %
StatinCarotid Aortic Infrainguinal
11 56 20 Atorvastatin
14 47 39 Fluvastatin
10 46 43 NR
21 42 37 NR
100 0 0 NR
100 0 0 NR
0 100 0 Atorvastatin
Fluvastatine
Pravastatin
Simvastatin
0 100 0 Atorvastatin
Fluvastatine
Pravastatin
Simvastatin
100 0 0 Atorvastatin
Fluvastatin
Lovastatin
Pravastatin
Simvastatin
4 85 11 NR
0 0 100 NR
24 35 41 Atorvastatin
Fluvastatine
Pravastatin
Rosuvastatin
Simvastatinmethods could be abstracted. In total, our meta-analysis included
data on 13,574 patients undergoing vascular surgery and receiving
statin therapy (4651 patients) or control (placebo or no statin;
8923 patients). Pooled analysis of all the 10 studies demonstrated
that statin therapy was statistically significantly associated with
lower mortality in fixed effects models (OR, 0.44; 95% confidence
interval [CI], 0.33-0.57; P  .00001). There was minimal study
heterogeneity (P  .11) and, accordingly, little difference in the
pooled result from random-effects modeling (OR, 0.43; 95% CI,
0.30-0.62; P  .00001). Exclusion of any single study from the
analysis did not substantively alter overall result of our analysis.
When data from randomized trials (597 patients) and nonrandom-
ized studies (12,977 patients) were separately pooled using a fixed
effects model, statin therapy reduced mortality statistically nonsig-
nificantly (OR, 0.47; 95% CI, 0.18-1.21; P  .12) and was
statistically significantly associated with lower mortality (OR, 0.44;
95% CI, 0.33-0.58; P  .00001), respectively. There was no
evidence of significant publication bias (P  .63) by an adjusted
rank-correlation test.
The results of our analysis suggest that preoperative statin
therapy may reduce postoperative mortality in patients undergoing
vascular surgery, which was robust in sensitivity analyses. The data
from only the two randomized trials, however, are less robust,
primarily due to the small number (597) of enrolled patients.More
randomized trials are needed to confirm the results of the present
meta-analysis.
djustment method Follow-up OR (95% CI)
eeded 30 days 0.33 (0.01-8.21)
eeded 30 days 0.48 (0.18-1.30)
0.47 (0.18-1.21)
R In hospital 0.07 (0.01-0.53)
djusted MLR In hospital 0.35 (0.18-0.68)
djusted MLR In hospital 0.69 (0.14-3.39)
djusted MLR In hospital 0.23 (0.06-0.91)
djusted MLR 30 days and/or
in hospital
0.50 (0.07-3.51)
djusted MLR 30 days and/or
in hospital
1.40 (0.50-3.90)
R 30 days 0.22 (0.05-0.96)
onditional logistic
gression
30 days 0.22 (0.10-0.47)
eighting 30 days 0.81 (0.41-1.61)
R 30 days 0.45 (0.27-0.75)
0.44 (0.33-0.58)
0.44 (0.33-0.57)A
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Reply
We read the comments from Takagi et al with great interest.
Their letter outlines an interesting and thought-provoking meta-
analysis demonstrating the protective benefits of preoperative statin
therapy in patients with noncoronary vascular disease. In addition to
the studies cited in our manuscript, this letter cites several other
important sources which add credence to our hypothesis regarding
the influence of statin-class drugs on operative outcomes and resource
utilization after aneurysm surgery. Takagi et al should be commended
for this analysis, and we would urge the authors to consider a robust
publication of the methodology and data.
There exists a considerable body of literature demonstrating a
protective benefit attributable to statin therapy in patients with both
central and peripheral vascular disease. The data are so compelling,
that one might argue that there are ethical considerations to random-
ized trials as suggested by Takagi and colleagues. Statistical analyses
such as this, and comparative effectiveness research should be used to
develop evidence-based guidelines regarding the appropriate risk op-
timization of patients with vascular disease.
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